Experimental cocktail aims to tackle returning brain tumors

NCT ID NCT06061809

Ongoing Disease control Sponsor: ImmunityBio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study tests a mix of immune-boosting drugs, natural killer cells, and a device that sends low-intensity electric fields to the brain for people with glioblastoma that has come back after initial treatment. The trial has two parts: first, everyone gets the drug combo; second, participants are split into two groups, one adding the electric field device. The goal is to see if the combination is safe and can control the tumor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nogapendekin alfa inbakicept (N-803), PD-L1 t-haNK cells, bevacizumab, and tumor treating fields (TTFields)
What this could lead to: If successful, this combination could offer a new treatment option for people with recurrent glioblastoma, potentially slowing tumor growth and extending survival.
What could go wrong: This is an early-phase trial with only 34 participants, so results may not apply to everyone. The combination therapy may cause serious side effects, and it is not yet known if it works better than standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Chan Soon-Shiong Institute for Medicine (CSSIFM)

El Segundo, California, 90245, United States
Hoag Memorial Hospital Presbyterian

Newport Beach, California, 92663, United States
Providence Medical Foundation

Fullerton, California, 92835, United States
Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.